| Previous close | 12.40 |
| Open | 12.40 |
| Bid | 10.65 |
| Ask | 11.15 |
| Strike | 52.50 |
| Expiry date | 2024-07-19 |
| Day's range | 12.40 - 12.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 512 |
ZacksBristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
ZacksBristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Business WireBristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
© 2024 Yahoo. All rights reserved.